Available online 5 December 2022, 103894

Evidence supporting HX575 use has been gained over 15 years of clinical practice

Several real-world studies have shown HX575 is well tolerated in CIA treatment

Extensive experience can reassure clinicians on the use of HX575 in practice

Switching to HX575 from another ESA is well tolerated across indications

Biosimilars offer the potential to expand patient access and reduce healthcare costs. Therefore, it is of importance that clinicians and patients are reassured about their efficacy and safety in practice. In 2007, Binocrit® (HX575; Sandoz GmbH, Kundl, Austria) was the first epoetin alfa biosimilar approved for use in chemotherapy induced anaemia (CIA), chronic renal failure (CRF), and more recently myelodysplastic (MDS) anaemia. Since its approval, there has been a plethora of data demonstrating the well-tolerated safety profile of HX575. This review will outline the safety results collected from key studies that have added to the extensive HX575 (Binocrit® unless otherwise stated) clinical experience. With a focus on all approved indications, we will review the safety data collected across a range of study types, to further consolidate the reassurance for the use of HX575 in these indications.

Binocrit®

biosimilars

chemotherapy-induced anaemia

chronic kidney disease

epoetin alfa

HX575

myelodysplastic anaemia

© 2022 The Authors. Published by Elsevier B.V.